Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company.
Lilly and Innovent will collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade.
The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.
|Searching for more deal information? Current Partnering offers the following options:|
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
As a part of the agreement, Innovent will lead the development and manufacturing for the China market, while Lilly will be responsible for commercialization of the three potential medicines.
Innovent also has co-promotion rights.
Lilly will contribute its cMet monoclonal antibody gene for possible treatment of non-small cell lung cancer.
Separate from this collaboration, Lilly will continue the development of its cMet monoclonal antibody program outside of China.
Innovent will contribute its monoclonal antibody targeting protein CD-20 for investigation in hematologic malignancies.
Innovent has received investigational new drug approval in China to begin Phase I development of this potential therapy.
Innovent will contribute a pre-clinical immuno-oncology molecule for development in China.
The companies have agreed that Lilly will be responsible for development, manufacturing and commercialization of this molecule outside of China.
Lilly will also receive rights to develop and commercialize up to three pre-clinical bispecific immuno-oncology molecules outside of China.
Under the terms of the agreement, Innovent will receive a total upfront payment of $56 million.
Lilly could also issue future payments exceeding $400 million for the pre-clinical immuno-oncology molecule if the product reaches certain development, regulatory and sales milestones.
Sales royalties and other payments would occur on certain products if commercialized.
Further financial terms were not disclosed.